ロード中...
Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab
Elotuzumab is a humanized monoclonal antibody targeting the extracellular domain of signaling lymphocytic activation molecule F7 (SLAMF7) highly expressed in multiple myeloma cells. Upon binding to myeloma cells, elotuzumab exerts its cytotoxic effects through antibody-dependent cellular cytotoxicit...
保存先:
| 出版年: | Ther Adv Hematol |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publications
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5026292/ https://ncbi.nlm.nih.gov/pubmed/27695618 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620716657993 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|